Gyre Therapeutics (NASDAQ:GYRE) Announces Earnings Results, Misses Estimates By $0.03 EPS

Gyre Therapeutics (NASDAQ:GYRE) announced its quarterly earnings data on Monday. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.03), Zacks reports. Gyre Therapeutics had a negative net margin of 84.57% and a negative return on equity of 118.43%.

Gyre Therapeutics Stock Performance

Shares of GYRE traded up $0.17 during midday trading on Monday, hitting $12.28. The company had a trading volume of 75,810 shares, compared to its average volume of 74,132. The company’s 50-day simple moving average is $11.27 and its 200-day simple moving average is $12.30. Gyre Therapeutics has a 1 year low of $8.26 and a 1 year high of $19.00.

Insider Activity

In other news, President Songjiang Ma sold 2,000 shares of the firm’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $12.70, for a total transaction of $25,400.00. Following the sale, the president now owns 2,928,467 shares of the company’s stock, valued at approximately $37,191,530.90. This trade represents a 0.07 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In the last quarter, insiders sold 38,054 shares of company stock worth $431,157. 19.52% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Gyre Therapeutics

An institutional investor recently raised its position in Gyre Therapeutics stock. Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) by 40.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,937 shares of the company’s stock after acquiring an additional 1,996 shares during the period. Bank of America Corp DE’s holdings in Gyre Therapeutics were worth $84,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Noble Financial started coverage on Gyre Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating for the company.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.